Lupin Stock

Lupin Liabilities

The The Liabilities of Lupin (LUPIN.NS) as of Aug 25, 2026 is 120.01 B INR. In the previous year, The Liabilities was 97.07 B INR — a change of 23.64% (higher).

Liabilities

120.01 BINR

YoY

23.64%

Last updated:

In 2026, Lupin's total liabilities amounted to 120.01 B INR, a 23.64% difference from the 97.07 B INR total liabilities in the previous year.

The Lupin Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
127.28 B INR
Jan 1, 2019
142.07 B INR
Jan 1, 2020
124.47 B INR
Jan 1, 2021
98.07 B INR
Jan 1, 2022
96.68 B INR
Jan 1, 2023
104.91 B INR
Jan 1, 2024
97.07 B INR
Jan 1, 2025
120.01 B INR
The Lupin Liabilities history
YEARLiabilitiesYoY
120.01 BINR+23.64%
97.07 BINR-7.48%
104.91 BINR+8.52%
96.68 BINR-1.42%
98.07 BINR-21.21%
124.47 BINR-12.39%
142.07 BINR+11.62%
127.28 BINR-2.91%
131.10 BINR+14.38%
114.62 BINR+180.39%
40.88 BINR+24.83%
32.75 BINR
Access this data via the Eulerpool API

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Lupin's Liabilities

Lupin's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Lupin's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Lupin's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Lupin's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Lupin’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Lupin stock

The Liabilities of Lupin is 120.01 B INR in 2026.

The Liabilities of Lupin changed from 97.07 B INR to 120.01 B INR, representing a 23.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Lupin since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Lupin historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Lupin

All Key Metrics — Lupin